Some of the highlights that will be presented during the educational and scientific program at Europe's prime minister medical oncology meeting include:
Molecular analysis for target discovery: Identification of 'Achilles' heel'
MicroRNa, SiRNA libraries
Protein array
Innovation in titty cancer
Modulation of resistance to anti-Her2 therapies
Evaluation of prognostic markers on circulating tumour cells
New targets for three-bagger negative tumors
Stem cell as a potency target
Tools in daily clinical practice to improve treatment
Tailoring therapy in lung cancer
Medical implications of resistance to EGFR
Personalized cancer therapies for non-EGFR receptor-dependent tumors
New pathways in targeted therapy
IGF-1, PI 3, PARP, Met
Optimal integration of newer agents in the treatment of advanced CRC
Genomic and pharmacogenetic markers for treatment decision
Upfront serial vs. combination chemotherapy
Renal cell cancer
VEGF biology and resistance
mTOR
Tackling future issues
Hitting the cell in ovarian and endometrial cancers
PARP, mTOR, etc
Head and neck cancer
Viruses: Prevention and therapy
Innovations in radiation oncology (IMRT and look-alike guided radiotherapy)
How to integrate EGFR inhibitors and beyond
Hematological malignancies
The role of high-dose therapy and allografting stemcell transplanting in the era of '-nibs' and '-mabs'
Communication skills in advanced crab care
o The use of communication skills: Lessons derived from microanalytical studies
Advances in soft tissue sarcoma, GIST and beyond
GIST - the role of adjuvant therapy and mutational analysis in treatment decision-making
Molecular biology and targeted therapy of sarcomas
Hyperthermia improves local control of STS - where future?
Emerging therapies for rare tumors
Neuroendocrine tumors, HCC, thyroid cancer, papillary RCC
Assessing, reporting and managing the safety of cancer drugs
Detecting safety signals
The function of pharmacogenetics in predicting and managing toxicity
Handling side effects of targeted therapies
Integration of targeted therapies with radiation
Where we are with radiation modifiers?
Unplanned analysis of molecular studies
Harmful or safe?
Cancer patients
o Should all receive prophylactically antithrombotic therapy?
o Dealing with hard cases in daily clinical practice
New developments in myeloma
Prognostic factors and the role of novel drugs
The status of transplantation
Glioma
From tomography to management
Recent progress in immunotherapy
Anti cancer vaccines
Combining immunotherapy with classical antineoplastic therapy
Advanced prostate genus Cancer
The ever-changing face of hormonal therapy
Diabetes and cardiovascular disease in prostate cancer survivors
Latest on oncology in developing countries
Cancer encumbrance and the role of prevention
Balancing costs and benefits in malignant neoplastic disease therapy and prevention
Drug development
How to recognize a promising drug: The role of clinical and biologic endpoints
The persona of regulatory bodies in the do drugs approval process
The Highlights of the day session: summary roger Huntington Sessions of topics from the preceding day aiming to give an overview of the to the highest degree interesting and important points to emerge from previous sessions.
Late-breaking abstracts: oral roger Huntington Sessions to represent latest research studies with new research findings
Controversy roger Sessions will make lively discussions on hot topics.
The seventh ESMO Patient Seminar where patients will have the chance to meet oncologists and hear about the conditions of cancer treatment in Europe, comparing conditions in Eastern and Western countries; discuss and face up doctors around the consequences of cancer the Crab therapy, instruct the approaches to long-term survivorship and the next perspective of cancer treatments
Numerous Educational Sessions to submit state-of-the-art oncology.
The fifth slew of ESMO Designated Centers of Integrated Oncology and Palliative Care will be announced as centers of excellence for patient precaution in Europe.
A session on ESMO Clinical Recommendations will update current ESMO Guidelines on clinical practice for various tumour types.
Oncology Highlights of the most significant advances in cancer handling in 2008.
And� Her Majesty Queen Silvia of Sweden accepted to be the Patron of the thirty-third ESMO Congress and will give the welcome address during the Opening Ceremony
Meeting venue
The 33rd ESMO Congress will take place at the Stockholm International Fairs in �lvsj� (M�ssv�gen 1, SE-12580 Stockholm-�lvsj� located a short train journey from Stockholm Central Station.
The conference full broadcast is usable at http://www.esmo.org/activities/esmocongress/stockholm08/program_cng/
Accomodation
Congrex Sweden AB has been appointed by ESMO to manage hotel accommodation in relation to the thirty-third ESMO Congress For hotel reservation, please visit: http://www.esmo.org/activities/esmocongress/stockholm08/accommodation_cng/
About the European Society for Medical Oncology (ESMO)
The European Society for Medical Oncology (ESMO) is the leading European not-for-profit, professional organisation for medical oncology promoting multidisciplinary malignant neoplastic disease treatment around the world.
ESMO unites aesculapian oncologists and other oncology specialists, healthcare professionals, caregivers, patients, policy-makers and all the key stakeholders in a world-wide alliance committed to eradicating cancer and ensuring equal access to high quality treatment for all patients. Through state of the art education and training programs, ESMO plays an subservient role in providing the oncology community with the most up-to-date scientific research and information available. ESMO is dedicated to educating and supporting oncologists, optimizing patient guardianship, disseminating cancer-specific information to the public, and advocating patient rights. As an authoritative part in the fight against cancer, ESMO provides both the platform and the consultative expertise to influence national and international organizations as well as European authorities, in order to establish common standards for a multidisciplinary approach to cancer treatment. Through its flagship daybook, Annals of Oncology, ESMO publishes articles on all aspects of clinical oncology.
To find kO'd more about ESMO please visit hTTP://www.esmo.org/
Source: Vanessa Pavinato
European Society for Medical Oncology
More info
- Swiss HIV/AIDS Statement Could Have Serious Ramifications
- CMS Allocating $49M To High-Risk Health Insurance Pools In 31 States
- Survival Advantage Discovered In Mutant Testis Cells Behind Genetic Disorder
- Protecting The Hearts Of Patients With Muscular Dystrophy Using New Approach
- Preregistration Trainee Pharmacist Training Programme 2008/2009 - National Pharmacy Association, UK
